BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34894262)

  • 1. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
    Lucas JT; Tinkle CL; Huang J; Onar-Thomas A; Srinivasan S; Tumlin P; Becksfort JB; Klimo P; Boop FA; Robinson GW; Orr BA; Harreld JH; Krasin MJ; Northcott PA; Ellison DW; Gajjar A; Merchant TE
    Neuro Oncol; 2022 Jul; 24(7):1166-1175. PubMed ID: 34894262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
    Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
    Douglas JG; Barker JL; Ellenbogen RG; Geyer JR
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1161-4. PubMed ID: 15001259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
    Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
    Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors.
    Murphy ES; Merchant TE; Wu S; Xiong X; Lukose R; Wright KD; Qaddoumi I; Armstrong GT; Broniscer A; Gajjar A
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e655-60. PubMed ID: 22768993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
    Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
    Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue.
    Balachandar S; Dunkel IJ; Khakoo Y; Wolden S; Allen J; Sklar CA
    Pediatr Blood Cancer; 2015 Feb; 62(2):317-321. PubMed ID: 25346052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
    Kortmann RD; Kühl J; Timmermann B; Mittler U; Urban C; Budach V; Richter E; Willich N; Flentje M; Berthold F; Slavc I; Wolff J; Meisner C; Wiestler O; Sörensen N; Warmuth-Metz M; Bamberg M
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):269-79. PubMed ID: 10661332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
    von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
    J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.
    Dufour C; Foulon S; Geoffray A; Masliah-Planchon J; Figarella-Branger D; Bernier-Chastagner V; Padovani L; Guerrini-Rousseau L; Faure-Conter C; Icher C; Bertozzi AI; Leblond P; Akbaraly T; Bourdeaut F; André N; Chappé C; Schneider P; De Carli E; Chastagner P; Berger C; Lejeune J; Soler C; Entz-Werlé N; Delisle MB
    Neuro Oncol; 2021 Jul; 23(7):1163-1172. PubMed ID: 33377141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
    Leary SES; Packer RJ; Li Y; Billups CA; Smith KS; Jaju A; Heier L; Burger P; Walsh K; Han Y; Embry L; Hadley J; Kumar R; Michalski J; Hwang E; Gajjar A; Pollack IF; Fouladi M; Northcott PA; Olson JM
    JAMA Oncol; 2021 Sep; 7(9):1313-1321. PubMed ID: 34292305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma.
    Merchant TE; Schreiber JE; Wu S; Lukose R; Xiong X; Gajjar A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):554-61. PubMed ID: 25160611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma).
    Goldwein JW; Radcliffe J; Johnson J; Moshang T; Packer RJ; Sutton LN; Rorke LB; D'Angio GJ
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):899-904. PubMed ID: 8598368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of conformal radiation therapy for medulloblastoma.
    Merchant TE; Happersett L; Finlay JL; Leibel SA
    Neuro Oncol; 1999 Jul; 1(3):177-87. PubMed ID: 11550312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment results of adults and children with medulloblastoma NCI, Cairo University experience.
    Khalil EM
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):175-86. PubMed ID: 20029474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
    Mynarek M; von Hoff K; Pietsch T; Ottensmeier H; Warmuth-Metz M; Bison B; Pfister S; Korshunov A; Sharma T; Jaeger N; Ryzhova M; Zheludkova O; Golanov A; Rushing EJ; Hasselblatt M; Koch A; Schüller U; von Deimling A; Sahm F; Sill M; Riemenschneider MJ; Dohmen H; Monoranu CM; Sommer C; Staszewski O; Mawrin C; Schittenhelm J; Brück W; Filipski K; Hartmann C; Meinhardt M; Pietschmann K; Haberler C; Slavc I; Gerber NU; Grotzer M; Benesch M; Schlegel PG; Deinlein F; von Bueren AO; Friedrich C; Juhnke BO; Obrecht D; Fleischhack G; Kwiecien R; Faldum A; Kortmann RD; Kool M; Rutkowski S
    J Clin Oncol; 2020 Jun; 38(18):2028-2040. PubMed ID: 32330099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
    Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
    J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.